Thumbnail
Access Restriction
Subscribed

Author Olson, Katherine E. ♦ Bade, Aditya N. ♦ Schutt, Charles R. ♦ Dong, Jingdong ♦ Shandler, Scott J. ♦ Boska, Michael D. ♦ Mosley, R. Lee ♦ Gendelman, Howard E. ♦ Liu, Yutong
Source SpringerLink
Content type Text
Publisher Springer US
File Format PDF
Copyright Year ©2016
Language English
Subject Domain (in DDC) Technology ♦ Medicine & health
Subject Keyword Magnetic resonance imaging (MRI) ♦ manganese enhanced MRI (MEMRI) ♦ MPTP ♦ inflammation ♦ glial activation ♦ neuroprotection ♦ Neurosciences ♦ Neurology ♦ Neurosurgery ♦ Neurobiology
Abstract Neuroprotective immunity is defined by transformation of T-cell polarity for therapeutic gain. For neurodegenerative disorders and specifically for Parkinson’s disease (PD), granulocyte-macrophage colony stimulating factor or vasoactive intestinal peptide receptor 2 (VIPR2) agonists elicit robust anti-inflammatory microglial responses leading to neuronal sparing in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-intoxicated mice. While neurotherapeutic potential was demonstrated for PD, there remain inherent limitations in translating these inventions from the laboratory to patients. One obstacle in translating such novel neurotherapeutics centers on the availability of suitable noninvasive methods to track disease progression and therapeutic efficacy. To this end, we developed manganese-enhanced magnetic resonance imaging (MEMRI) assays as a way to track a linkage between glial activation and VIPR2 agonist (LBT-3627)-induced neuroprotective immunity for MPTP-induced nigrostriatal degeneration. Notably, LBT-3627-treated, MPTP-intoxicated mice show reduced MEMRI brain signal intensities. These changes paralleled reduced astrogliosis and resulted in sparing of nigral tyrosine hydroxylase neurons. Most importantly, the data suggest that MEMRI can be developed as a biomarker tool to monitor neurotherapeutic responses that are relevant to common neurodegenerative disorders used to improve disease outcomes.
ISSN 19337213
Age Range 18 to 22 years ♦ above 22 year
Educational Use Research
Education Level UG and PG
Learning Resource Type Article
Publisher Date 2016-06-21
Publisher Institution American Society for Experimental NeuroTherapeutics
Publisher Place New York
e-ISSN 18787479
Journal NeuroRX
Volume Number 13
Issue Number 3
Page Count 12
Starting Page 635
Ending Page 646


Open content in new tab

   Open content in new tab
Source: SpringerLink